跳至主要内容
临床试验/ACTRN12608000248369
ACTRN12608000248369已完成3 期

The role of Gabapentin in the treatment of refractory chronic dry cough: A randomised double-blind placebo-controlled study.

Hunter New England Area Health Service0 个研究点目标入组 56 人开始时间: 2008年5月15日最近更新:
适应症

试验速览

阶段
3 期
状态
已完成
入组人数
56

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional
分配方式
Randomised controlled trial
主要目的
Treatment
盲法
Blinded (masking used)

入排标准

年龄范围
18 Years 至 80 Years(—)
性别
All

入选标准

  • Persistent non-productive cough of more than 8 weeks duration,
  • Male or female between ages of 18 and 80 years,
  • Non-smoker or ex-smoker with less than 10 pack years,
  • To have been well during the 4 weeks prior to study entry,
  • Informed consent obtained.

排除标准

  • Productive cough,
  • Current smoker,
  • Smoking history >10 pack years,
  • Pregnancy/breast feeding,
  • Other respiratory disease, eg: bronchiectasis, COPD.
  • Inability to attend study visits
  • Respiratory tract infection during month prior to randomisation
  • Impaired liver function at Visit 1 as shown by Aspartate aminotransferase (AST), an enzyme normally present in liver and heart cells and alanine aminotransferase (ALT). If the liver is injured, the liver cells spill the enzymes into blood, raising the enzyme levels in the blood and signaling liver damage.
  • Therefore, an AST, ALT, alkaline phosphatase or total bilirubin greater than 2 times the upper limit of normal will exclude a participant.

研究者

相似试验